Adaptimmune Therapeutics PLC (ADAPY): Revenue
Not updated since 2024-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
$178.03M
Year ended 2024-12-31
+207.1%
3-year compound annual growth
n/m
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2024-12-31 | $178.03M | +195.3% | 2025-03-24, From 2024-01-01 |
| 2023-12-31 | $60.28M | +122.0% | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | $27.15M | +341.5% | 2025-03-24, From 2022-01-01 |
| 2021-12-31 | $6.15M | +55.4% | 2024-03-06, From 2021-01-01 |
| 2020-12-31 | $3.96M | +252.8% | 2023-03-06, From 2020-01-01 |
| 2019-12-31 | $1.12M | -98.1% | 2022-03-14, From 2019-01-01 |
| 2018-12-31 | $59.51M | +57.3% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $37.83M | +166.5% | 2019-02-27, From 2017-01-01 |
| 2016-12-31 | $14.20M | n/a | 2019-02-27, From 2016-01-01 |
| No annual figure between 2015-06-30 and 2016-12-31. | |||
| 2015-06-30 | $9.87M | n/m | 2018-03-15, From 2014-07-01 |
| 2014-06-30 | $825.0K | n/a | 2017-03-13, From 2013-07-01 |